Competing interests
R.E.S.: Research funding: Rafael Pharmaceuticals, BMS, GSK, and Seattle Genetics. E.R.P. has nothing to disclose. F.V. receives research funding from NCI, CRISP Therapeutics, Allogene, Geron corporation and from the Moonshot program at MDACC. L.F. has nothing to disclose. J.R.W. has received research funding from Kite, BMS, Novartis, Genentech, AstraZeneca, Morphosys/Incyte, ADC Therapeutics, Calithera, Kymera; consulting: Kite, BMS, Novartis, Genentech, AstraZeneca, Morphosys/Incyte, ADC Therapeutics, Calithera, Merck, Abbvie/GenMab, SeaGen, MonteRosa, Iksuda. S.S.N. has received research support from Kite/Gilead, BMS, Cellectis, Poseida, Allogene, Unum Therapeutics, Precision Biosciences, and Adicet Bio; served as Advisory Board Member/Consultant for Kite/Gilead, Merck, Novartis, Sellas Life Sciences, Athenex, Allogene, Incyte, Adicet Bio, BMS, Legend Biotech, Bluebird Bio, Fosun Kite, Sana Biotechnology, Caribou, Astellas Pharma, and Morphosys; has received royalty income from Takeda Pharmaceuticals; has stock options from Longbow Immunotherapy, Inc; and has intellectual property related to cell therapy. P.S. has received research support from Sobi, Astrazeneca Acerta, ADC Therapeutics, ALX Oncology. Advisory board/consultancy: Hutchinson Medipharma, Roche Genentech, Astrazeneca Acerta, ADC Therapeutics, TG Therapeutics, Kite Gilead, Sobi, Incyte Morphosys. M.R.G. reports research funding from Sanofi, Kite/Gilead, Abbvie and Allogene; consulting for Abbvie; honoraria from Tessa Therapeutics, Monte Rosa Therapeutics and Daiichi Sankyo; and stock ownership of KDAc Therapeutics. C.R.F. is consultant for Abbvie, Bayer, BeiGene, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech/Roche, Genmab, Gilead, Karyopharm, N-Power Medicine, Pharmacyclics/Janssen, SeaGen, Spectrum, has stock Options with Foresight Diagnostics, N-Power Medicine, has research Funding from 4D, Abbvie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceutical, Kite, Morphosys, Nektar,Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation, Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research. L.M.S. has nothing to disclose. I.I.W. has provided consulting or advisory roles for AstraZeneca/MedImmune, Bayer, Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Guardant Health, HTG Molecular Diagnostics, Merck, MSD Oncology, OncoCyte, Jansen, Novartis, Flame Inc, and Pfizer; has received grants and personal fees from Genentech/Roche, Bristol Myers Squibb, AstraZeneca/MedImmune, HTG Molecular, Merck, and Guardant Health; has received personal fees from GlaxoSmithKline and Oncocyte, Daiichi-Sankyo, Roche, Astra Zeneca, Regeneron, Sanofi, Pfizer and Bayer; has received research funding to his institution from 4D Molecular Therapeutics, Adaptimmune, Adaptive Biotechnologies, Akoya Biosciences, Amgen, Bayer, EMD Serono, Genentech, Guardant Health, HTG Molecular Diagnostics, Iovance Biotherapeutics, Johnson & Johnson, Karus Therapeutics, MedImmune, Merck, Novartis, OncoPlex Diagnostics, Pfizer, Takeda, and Novartis. S.A. has received research support paid to her institution from Tessa Therapeutics, SeaGen, Merck, Xencor, Chimagen; Advisory committee member: Sanofi, SeaGen, Tessa Therapeutics; Consultancy: Novartis, Myeloid Therapeutics, Servier, Chimagen. R.N. has received honoraria from Incyte for speaker/preceptorship. F.B.H. has nothing to disclose. M.N. has nothing to disclose. M.L.M-P. has nothing to disclose.